MR

Madhumita Roy

Active Director Director DIN 07657582
DIN 07657582 First appointment Apr 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Madhumita Roy

Data last updated:

Madhumita Roy is a Director at Raybros Medicaments Private Limited (since 2018). The company operates in Pharma. Raybros Medicaments Private Limited reported revenue of ₹2.74 Cr (FY 2024).

DIN 07657582
Primary Designation Director
Industry Pharma
First Appointment 17 Apr 2018
Oldest Company Age 8 yrs
Largest company Raybros Medicaments Private Limited · ₹2.74 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Raybros Medicaments Private Limited U33100MH2018PTC308142
Director17 Apr 20182018₹2.74 Cr (FY 2024)Active

Board colleagues of Madhumita Roy

Directorship timeline

Open interactive timeline →
Raybros Medicaments Private Limited
Premium access

Shareholding and investment profile for Madhumita Roy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Madhumita Roy

Madhumita Roy currently holds 1 directorship: Raybros Medicaments Private Limited (Director, since 17 Apr 2018, revenue ₹2.74 Cr (FY 2024)).

Madhumita Roy was first appointed on 17 Apr 2018 as Director at Raybros Medicaments Private Limited.

The current boards of Madhumita Roy's companies include Robin Sarothi Roy (Raybros Medicaments Private Limited), Sarothi Roy (Raybros Medicaments Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available